CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02473809
NCT02473809Phase 4Completed
CompareCT.gov

The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

University of Aarhus·interventional·Posted Jun 17, 2015·Updated Sep 26, 2018

In Brief

A Phase 4 clinical trial evaluating Liraglutide and Placebo for Diabetes Complications and Osteoporosis. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2 diabetes may cause multiple complications, and it is well known that patients with type 2 diabetes have a higher risk of fractures. If Liraglutide can be demonstrated to have a positive effect on bone, this may be one among other factors to consider before the decision about specific treatment of type 2 diabetes is made for the individual patient.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Complications, Osteoporosis
CountriesDenmark
CollaboratorsAarhus University Hospital, Novo Nordisk A/S

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 17, 2015
Enrollment StartAug 1, 2015
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.0 years ago

Interventions

Liraglutidedrug

Once daily

Placebodrug

Once daily